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Background/Objective: The incidence of psoriasis vulgaris in Asians is estimated at 0.05e0.30%. Studies in
North America and Europe demonstrated that adalimumab, a fully human monoclonal IgG1 antibody, is
an efﬁcacious treatment for psoriatic arthritis and chronic plaque psoriasis. The aim of this study was to
evaluate the efﬁcacy and safety of adalimumab in treating psoriatic arthritis (PsA) in patients who have
moderate to severe psoriasis.
Methods: This was a retrospective study comprising 12 patients with chronic plaque psoriasis and
psoriatic arthritis who were treated with adalimumab between October 2008 and February 2013. All had
failed treatment with conventional systemic agents. Patients were started on adalimumab 40 mg every
other week.
Results: At week 12, 3 of 12 patients (25%) achieved a 75% improvement in their Psoriasis Area and
Severity Index (PASI 75). With regard to PsA, at week 12, the improved Psoriatic Arthritis Response
Criteria (PsARC) response was experienced by 75% (9 of 12) of the patients. Mean improvement in
Dermatology Life Quality Index (DLQI) was 42%. Five of 12 patients (42%) experienced adverse events,
which were generally mild.
Conclusion: Patients with refractory psoriatic arthritis appeared to be responsive to adalimumab. The
achievement rate of PsARC in our study was comparable to the efﬁcacy reported in previous literature.
Detection of antinuclear antibodies was not associated with the responsiveness in this trial, nor did it
inﬂuence the potential for adverse effects. Adalimumab as a monotherapy is generally effective and safe.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Psoriasis is a common, chronic, immune-mediated disorder of the
skin that affects 2e3% of the populationworldwide.1,2 In Asians, the
incidence of psoriasis vulgaris is estimated at 0.05e0.3%.3,4 Patients
present with a broad range of clinical manifestations with symp-
toms that vary in severity. The most common form of psoriasis is
plaque-type psoriasis, seen in up to 80% of patients and charac-
terized by patches of raised, red lesions covered by silver-white
scales. Patients with psoriasis report a reduction in physical and
mental functioning, resulting in a severely impaired quality of life,y have no ﬁnancial or non-
tter or materials discussed in
ogy, Chang Gung Memorial
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ng).
cal Association. Published by Elsevcomparable with that seen in patients with cancer, arthritis, hy-
pertension, heart disease, diabetes, and depression.1,2
Long-term use of common disease-modifying antirheumatic
drugs (DMARDs), including methotrexate (MTX), cyclosporine, and
retinoids, is limited by potential adverse effects and cumulative
organ toxicities.5,6 Adalimumab has been investigated for the
treatment of moderate to severe chronic plaque psoriasis based on
recent ﬁndings implicating T lymphocytes and tumor necrosis
factor (TNF) in the pathogenesis of plaque psoriasis.7,8 Adalimumab
is a recombinant, fully human, anti-TNF-a monoclonal immuno-
globulin G1 antibody, which binds both soluble and cell-bound
forms of TNF-a with high afﬁnity and speciﬁcity. Adalimumab
neutralizes TNF-a activity by directly blocking its interaction with
p55 and p75 cell surface TNF-a receptors as well as by modulating
biological responses that are induced or regulated by TNF-a.5,9,10
Previous studies of adalimumab in the treatment of psoriasis
have been performed on patients, with moderate to severe psori-
asis, who were selected under strict inclusion and exclusionier Taiwan LLC. All rights reserved.
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adalimumab to treat psoriatic arthritis (PsA) in patients who have
moderate to severe psoriasis.Methods
This was a retrospective study of all patients with chronic plaque
psoriasis and PsA who were treated with adalimumab between
October 2008 and February 2013 in the Department of Derma-
tology, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan. All of
them underwent screening in order to exclude active or latent in-
fections prior to adalimumab treatment. Information on de-
mographics and psoriasis history, including age, sex, duration, and
family history of psoriasis, presence of PsA, previous treatments,
and Psoriasis Area and Severity Index (PASI), was recorded.
Patients were started on adalimumab when they failed to
respond or stopped responding to at least one other systemic
treatment for psoriasis. Because of the severity of the patients'
disease, there was no washout time after treatment with previous
systemic agents. According to the guidelines for the treatment of
PsA with adalimumab, a dose of 40 mg was self-administered
subcutaneously every other week, at Week 0, Week 2, Week 4,
Week 6, Week 8, and Week 10.10
Efﬁcacy was evaluated in all patients at baseline (Week 0) and at
Week 2, Week 4, Week 8, and Week 12. Psoriasis disease activity
was measured by calculating the PASI score. The PsA response
achievement rate was deﬁned, in accordance with the Psoriatic
Arthritis Response Criteria (PsARC),11 as the percentage of patients
who showed improvement in two or more of the following ways:
(1)  30% decrease in the number of swollen joints counted;
(2)  30% decrease in tender joints counted; (3) improvement in
patient's global assessment of disease activity; or (4) improvement
in physician's global assessment of disease activity. To qualify as an
improved response, the patient must not have shown analogously
deﬁned worsening in any of these ways and must have shown
improvement on at least one joint count. In addition to the responseTable 1 Patient characteristics and baseline assessments.
Age
(y)
Sex PASI score DLQI Family
history
Psoriatic arthritis
Swelling/76 Pain/78 Du
A 29 F 23.2 25 Yes 3 5 1
B 50 M 21.5 23 Yes 5 19 1
C 56 M 42.9 20 Yes 8 11 18
D 27 M 51.6 11 Yes 1 2 2
E 47 M 18.3 15 No 10 18 3
F 53 F 14.4 15 No 0 24 5
G 40 F 14.8 1 No 6 35 10
H 37 F 28 27 No 5 29 13
I 54 F 12.2 8 No 0 2 10
J 37 M 21.8 21 No 20 22 20
K 45 F 20.6 17 No 51 31 10
L 25 M 25.5 15 No 18 19 11
Mean ± SD 41.7
10.84
24.6
11.70
16.5
7.43
10.6
14.21
18.1
11.13
8.7
6.4
BID ¼ twice a day; CRP¼ C-reactive protein; DLQI ¼ Dermatology Life Quality Index; ESR
Severity Index; QD ¼ every day; QOD ¼ every other day; QW ¼ once a week; SD ¼ stanachievement rate, the Dermatology Life Quality Index (DLQI), a self-
administered questionnaire, was evaluated in all patients to assess
the effect of the skin disease on their daily activities.12
In total, 12 patients were included in the study [6 men (50%), 6
women (50%), mean age 41.7 years, range 25e59 years]. All of them
completed the 12-week treatment. The mean baseline PASI score
was 24.6, [standard deviation (SD) 11.7], and the initial PASI score of
each patient was > 10. Five patients (42%) had a family history of
psoriasis. With regard to PsA, the overall population of treated
patients had baseline scores of 11 (SD 14) for swollen joint count, 18
(SD 11) for tender joint count, and 16.5 (SD 7.43) for DLQI. All pa-
tients had more than three joints involved at the outset of adali-
mumab treatment (Table 1). These values are consistent with long-
standing moderate to severe psoriasis and PsA.
Safetyassessmentswereconducted throughout the study.Adverse
events were assessed at Week 0,Week 2,Week 4,Week 8, andWeek
12 during each visit. Laboratory evaluations, including measurement
of erythrocyte sedimentation rates (ESR), C-reactive protein (CRP)
levels, and antinuclear antibody (ANA) levels were also recorded.
Results
Previous treatment
Of the 12 patients, four (33%) had been treated with MTX, ﬁve (42%)
with cyclosporine, 7 (58%) with acitretin, one (8%) with penicilla-
mine, six (50%) with nonsteroidal anti-inﬂammatory drugs, four
(33%) with leﬂunomide, and one (8%) with prednisolone. One pa-
tient (8.3%) received subcutaneous etanercept prior to starting
adalimumab treatment. The mean number of previous systemic
treatments was 1.6 (range 0e4; Table 1).
Efﬁcacy
At Week 12, 10 of 12 patients (83%) had achieved an improvement
rate of at least 25% on the PASI score (PASI 25), seven patients (58%)ESR,
mm/h
CRP,
mg/L
Previous systemic
medication
Psoriasis activity
during the trial
ration/y
67 9 Cyclosporin
(100e200 mg QD)
Initial aggravation
14 8 Acitretin (30 mg QOD) Initial aggravation
64 49 Acitretin (25 mg QD)
MTX (15 mg QW)
Gradual improvement
8 21 Acitretin (35 mg QD)
Etanercept
Gradual improvement
124 189.89 Acitretin (25 mg QD)
Cyclosporin (100 mg QD)
Leﬂunomide (200 mg BID)
Prednisolone (5 mg BID)
Progression
15 < 3.16 MTX (7.5 mg QD) Gradual improvement
36 5.01 MTX (10 mg QW)
Leﬂunomide (200 mg QD)
Gradual improvement
52 56 Penicillamine (300 mg BID)
Cyclosporin (200 mg QD)
Initial aggravation
12 < 3.16 Acitretin (25 mg QD)
MTX (7.5 mg QD)
Gradual improvement
1 < 3.16 Cyclosporine (100 mg BID)
Acitretin (35 mg QD)
Initial aggravation
64 21 Acitretin (10 mg BID) Gradual improvement
2 < 3.17 MTX (7.5 QW)
Leﬂunomide (200 mg QD)
Gradual improvement
1
38.3
37.10
30.6
51.88
¼ erythrocyte sedimentation rate; MTX ¼methotrexate; PASI¼ Psoriasis Area and
dard deviation.
Table 2 Improvement of psoriasis activity as assessed by Psoriasis Area and Severity Index and Dermatology Life Quality Index.
PASI score DLQI
Week 0 Week 12 Improvement, % Week 0 Week 12 Improvement, %
A 23.2 15.4 34 25 12 52
B 21.5 17.9 17 23 12 48
C 42.9 30.1 30 20 19 5
D 51.6 15.3 70 11 2 82
E 18.3 32.4 77 15 13 13
F 14.4 2.8 80 15 3 80
G 14.8 3.8 74 1 1 0
H 28 19 32 27 16 41
I 12.2 1.6 87 8 4 50
J 21.8 8.1 63 21 10 50
K 20.6 7.6 63 17 8 53
L 25.5 1.6 94 15 10 33
Mean ± SD 24.6
11.70
13.0
10.62
16.5
7.43
9.2
5.72
DLQI ¼ Dermatology Life Quality Index; PASI¼ Psoriasis Area and Severity Index; SD ¼ standard deviation.
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patients (25%) achieved PASI 75. Among those whose PASI score
had improved at Week 12, there were four patients (33%) patients
with initial aggravation, seven patients (58%) with gradual
improvement, and one patient (8%) with persistent progression of
symptoms after beginning treatment with adalimumab (Table 1).
The mean PASI score improved from 24.6 to 13.0, corresponding to
a 47 % rate of improvement (Table 2). Moreover, three patients
(25%) received additional systemic agents during the study: one
received MTX, one received cyclosporine, and one received
narrowband ultraviolet radiation b (UVB) phototherapy combined
with MTX.
With regard to PsA, at Week 12, the improved PsARC response
was experienced by 75% (9 of 12) of the patients. The mean
reduction in count was 9 (from49 to 18) for tender joints, and of 7
(from 7 to 48) for swollen joints, respectively (Table 3). Further-
more, therapy with adalimumab considerably improved patients'
quality of life as assessed by DLQI, with average improvement from
16.5 to 9.2 at Week 12 (Table 2).
Safety
In our patients, adalimumab was generally well tolerated. No ma-
lignancy or infection serious enough to require hospitalization was
reported. Seven patients did not have any side effects during the
12-week treatment course. Three patients reported blurred vision,
two patients suffered from dizziness and malaise, and three pa-
tients experienced increased itchiness. One case each of upper
respiratory tract infection, tinnitus, folliculitis, and urticaria wasTable 3 Psoriatic arthritis response criteria measurements.
Pain Swelling Improvement (%) PGA
(%)
PsARC
Week 0 Week 12 Week 0 Week 12 Pain Swelling
A 5 3 3 0 40 100 30 þ
B 19 3 5 1 84 80 70 þ
C 11 4 8 1 64 88 30 þ
D 2 1 1 0 50 100 90 þ
E 18 11 10 3 40 70 50
F 24 73 0 0 204 No change 0 
G 35 21 6 3 40 50 40 þ
H 29 11 5 6 62 20 80 
I 2 0 0 7 100 100 70 
J 22 11 7 7 50 36 80 þ
K 31 17 51 3 45 82 80 þ
L 19 9 18 3 53 83 50 þ
PGA ¼ Patient Global Assessment; PsARC ¼ Psoriatic Arthritis Response Criteria.reported in four separate patients (Table 4). None of these
nonspeciﬁc adverse events led to interruption of the adalimumab
treatment.
All laboratory abnormalities were mild and none warranted
discontinuation of therapy. Mean ESR was 38.3 (SD 37.10) initially
and dropped to 21.5 (SD 29.22) at Week 12; mean CRP decreased
from 30.6 (SD 51.88) to 11.4 (SD 29.67). At baseline, ANA was un-
detectable in 11 patients, and two of these patients were found to
have weakly positive titer (1:40) at Week 12. Only one patient had
elevated titer (1:640) initially; the ANA titer of this patient
remained the same at Week 12.
Discussion
Adalimumab has been mainly investigated for the treatment of
moderate to severe psoriasis. Our study demonstrated that patients
who had chronic plaque psoriasis were responsive to adalimumab.
Furthermore, the observed improvement in DLQI, as well as in the
rate of PsARC responders, indicated that patients with PsA recal-
citrant to previous systemic treatment were also responsive to
adalimumab. No serious side effects leading to hospitalization or
cessation of treatment occurred. The presence of ANA did not affect
the resultant decrease in psoriasis disease activity.
Previous studies have shown that an initial loading dose of 80mg
followed by 40 mg every other week (eow) resulted in marked
improvement of PASI scores.13e15 In the ADalimumab Effectiveness
in Psoriatic Arthritis Trial (ADEPT), the double-blind, randomized,
placebo-controlled study conducted by Mease et al,16 also showed
49% achievement of PASI 75 atWeek 12. In another open-label studyTable 4 Adverse effects during the study.
Event N ¼ 12, n (%)
Without adverse events 7 (58.3)
Total adverse events 0
Serious infections 0
Adverse events leading to discontinuation 0
Adverse events
Blurred vision 3 (25.0)
URI symptom 1 (8.3)
Dizziness/malaise 2 (16,7)
Tinnitus 1 (8.3)
More pruritus 3 (25)
Urticaria 1 (8.3)
Folliculitis 1 (8.3)
Laboratory test
ALT > 3 times the ULN 0
ALT ¼ alanine aminotransferase; ULN ¼ upper limit of normal; URI ¼ upper respi-
ratory tract infection.
Table 5 Efﬁcacy result at Week 12 compared to previous studies.
Study design Treatment protocol Baseline mean PASI PASI 75 achievement, % PsARC achievement, %
Our study Retrospective 40 mg eow 41.7 25 75
ADEPT16 24-wk, randomized
double-blind, placebo-controlled
40 mg eow 7.4 49 62
ACCLAIM19 12-wk, open-label, uncontrolled 40 mg eow 11.7 47.1 70.1
STEREO18 12-wk, open-label, uncontrolled 40 mg eow Nonea Nonea 78
Papoutsaki et al17 24-wk, open-label, uncontrolled 40 mg QW 19.2 87 Nonea
Gordon et al23 12-wk, randomized, double-blind,
placebo-controlled
80 mg loading,
then 40 mg eow
16.7 53 Nonea
80 mg loading,
then 40 mg QW
14.5 80 Nonea
eow ¼ every other week; PASI¼ Psoriasis Area and Severity Index; PsARC ¼ Psoriatic Arthritis Response Criteria; QW ¼ once a week; ADEPT ¼ adalimumab effectiveness in
psoriatic arthritis trial; STEREO ¼ safety and efﬁcacy of adalimumab in patients with active psoriatic arthritisdan open-label, multinational study to evaluate the response to
every-other-week adalimumab when added to insufﬁcient standard therapy including patients who failed prior treatment with other TNF inhibitors; ACCLAIM ¼ a Canadian
open-label study to evaluate the safety and effectiveness of adalimumab when added to inadequate therapy for the treatment of psoriatic arthritis.
a Measurements were not assessed in the study.
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achieved in 87% of 30 patients.17 An open-label retrospective study
inTaiwan found that three of 13 patients (23%) had at least PASI 75 at
Week 12 after receiving adalimumab 40mgeowwith a loading dose
of 80 mg.15 In our study, 25% of the patients with a higher baseline
PASI score demonstrated PASI 75 achievement at Week 12. The
adalimumab dosage regimen used in our study to treat PsA, 40 mg
eow without an initial loading dose, was a lower dosage compared
to previous studies (Table 5).16e19,23 Asahina et al14 compared the
efﬁcacy of different adalimumab dosage regimens in their ran-
domized, placebo-controlled study. Among the three treatment
groups, composed of patients who received 40 mg eow, 80 mg eow,
or 40 mg eow following an 80-mg loading dose, the most rapid
response rate was found in patients receiving 40 mg eow plus the
loading dose. PASI 75 achievement was highest in the group
receiving 80 mg eow (81.0%).14 The reason the efﬁcacy obtained in
our study regarding plaque type psoriasis was lower than that ob-
tained in clinical trials might be due to the lower dosage.
Despite this ﬁnding, our study demonstrated an efﬁcacy in
treating PsA comparable to that of previous studies mainly con-
ducted in Europe and North America.16e19 At Week 12, PsARC
response achievement was 75%, which was very similar to that
reported in an open-label, uncontrolled trial of adalimumab in
patients with PsA with moderate to severe psoriasis19 (Table 5).
That signiﬁcant alleviation of joint pain and swelling, as well as of
functional disability, resulted from our adalimumab dosage
regimenwas also indicated by examination of the DLQI evaluations
and the patient and physician global assessments.
Analysis of PASI score trajectory shows that when adalimumab
treatment began, four patients (33%) exhibited initial aggravation,
seven patients (58%) had gradual improvement, and one patient (8%)
had persistent disease progression (Table 1). All of the patients who
exhibited initial aggravation had received at least one systemic
treatment before the trial, compared to 71% (5 in 7) of those who
gradually improved. In contrast to the usual protocol of a minimum
washout time of 2 weeks before adalimumab administration is
begun, our protocolwas to start adalimumab treatment immediately
after discontinuation of the previous treatment. One patient was
noted as having progression of PASI throughout the study, whereas
his symptoms of psoriatic arthritis were found to gradually improve.
This might imply that the response of psoriasis to adalimumab is not
completely parallel with the response of psoriatic arthritis.
During the course of our study, systemic medication in addition
to adalimumab was prescribed and administered to two patients,
namely a regimen of MTX. Among others treated with adalimumab
only, mean reduction rate of PASI was 54.6%, which was higher than
that (35.9%) in the total population. Two previous randomized
controlled studies in which concomitant use of DMARDs wasexcluded also showed a high rate of PASI 75 achievement.14,16 In
ACCLAIM trial (A Canadian open-label study to evaluate the safety
and effectiveness of adaLimumab when Added to Inadequate ther-
apy for the treatment of psoriatic arthritis), an open-label study,
concomitant use of DMARDs was allowed at stable, prestudy dos-
ages throughout the course. Response for patientswith active PsA, as
measured by percentages achieved in the Psoriatic Arthritis Joint
Activity Index, showed no difference between groups treated with
and without concomitant DMARDs.19
These studies suggest that adalimumab works effectively as a
monotherapy for treating PsA.
ANA has been reported to be associated with loss of response to
anti-TNF-a therapy. Pink et al20 found that patients on anti-TNF
therapy commonly developed ANA and anti-doubleestranded
DNA antibodies, which appears to be related to anti-TNF treatment
failure. In our study, there were 11 patients with undetectable ANA
titer and one with positive titer (1:640) at baseline. Two of the
patients who had undetectable baseline ANA testedweakly positive
(1:40) for ANA antibodies at Week 12. Their disease activity
responsiveness to adalimumab was no different from the others.
The single patient who had elevated baseline ANA continued to test
at the same positive level during the 12 weeks of treatment and yet
this patient exhibited fair improvement with respect to both pso-
riasis and PsA. None of our patients developed the lupus-like syn-
drome that has been reported in a few cases.21,22 In our study, ANA
was neither associated with responsiveness, nor did it inﬂuence the
manifestation of adverse side effects.
Unlike previously published studies, we did not design inclusion
and exclusion criteria in this retrospective study.16,23,24 Not only did
the small number of patients and short follow-up period make
doing so unfeasible, but most of our patients would not have ful-
ﬁlled the strict criteria in which patients selected for randomized
controlled trials must ﬁt. They had severe disease with mean PASI
of 24.6 initially, and their response in terms of joint manifestations
to previous systemic treatment had been poor. Randomized
controlled trials also require aminimumwashout period of 2 weeks
for nonbiological systemic therapies, which would not have been
possible in many of our patients due to the severity of their disease.
The concomitant use of topical agents and additional DMARDs
during the study are potential confounding factors that need to be
analyzed further.
In conclusion, our study is the ﬁrst to demonstrate that treat-
ment with adalimumab improved symptoms of psoriatic arthritis
and DLQI in Taiwanese patients with moderate to severe psoriasis.
Patients with recalcitrant PsA and psoriasis who would have been
ineligible for clinical trials showed a signiﬁcant positive response to
adalimumab in terms of both joint and skin manifestations, as well
as in terms of quality-of-life measures. Adalimumab was generally
P.-H. Kao et al. / Dermatologica Sinica 33 (2015) 119e123 123well tolerated and safety proﬁles were similar to what was
observed in other trials. The considerable efﬁcacy of adalimumab as
monotherapy demonstrated in our study is also consistent with
previous studies.
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